JPRN-UMIN000006057招募中4 期
Cohort study of capecitabine plus oxaliplatin (XELOX) together with Bevacizumab as the first-line therapy in advance or recurrent colorectal cancer. - Cohort study of capecitabine plus oxaliplatin (XELOX) together with Bevacizumab as the first-line therapy in advance or recurrent colorectal cancer.
Tokyo Medical University The third department of surgery0 个研究点目标入组 30 人开始时间: 2011年8月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patient who fall under the a package insert "contraindication" or "Contraindicaton in combination" with Bevacizumab , Oxaliplatin and Capecitabine. (2) Not appropriate for the study at the physician's assessment
研究者
相似试验
已完成
不适用
A phase II study of capecitabin plus oxaliplatin therapy (XELOX) for inoperable/advanced gastric cancer resistant/intolerable to fluoro-pyrimidine, CDDP, Taxane or CPT-11 (OGSG1403)unresectable/advanced gastric cancerJPRN-UMIN000016256Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)12
已完成
不适用
A Phase II Study of Capecitabine, Oxaliplatin (XELOX) and Bevacizumab for patient with high-risk Upper Rectal Cancer as Neo-Adjuvant chemotherapy.pper rectal cancerJPRN-UMIN000015765Cancer Institute Hospital of Japanese Foundation for Cancer Research19
Unknown
2 期
Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer PatientsColorectal CancerNCT02415829Fudan University55
已完成
不适用
Phase II study of Capecitabine + oxaliplatin(CapeOx) for elderly patients with untreated metastatic gastric cancer <TCOG GI-1601>ntreated metastatic gastric cancerJPRN-UMIN000022450The Tokyo Cooperative Oncology Group110
尚未招募
不适用
A feasibility study of capecitabine plus oxaliplatin (CapeOX) and S-1 plus oxaliplatin (SOX) for unresectable advanced or reccurent gastric cancerunresectable advanced or reccurent gastric cancerJPRN-UMIN000015258Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital40